发明公开
- 专利标题： GENE EDITING THERAPY FOR HIV INFECTION VIA DUAL TARGETING OF HIV GENOME AND CCR5
-
申请号： US18566468申请日： 2022-06-02
-
公开(公告)号： US20240261436A1公开(公告)日： 2024-08-08
- 发明人: Kamel KHALILI , Rafal KAMINSKI
- 申请人： TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
- 申请人地址： US PA Philadelphia
- 专利权人： TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
- 当前专利权人： TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
- 当前专利权人地址： US PA Philadelphia
- 国际申请： PCT/US22/31941 2022.06.02
- 进入国家日期： 2023-12-01
- 主分类号： A61K48/00
- IPC分类号： A61K48/00 ; A61K31/4985 ; A61K31/505 ; A61K31/52 ; A61K31/7068 ; A61P31/18 ; C12N9/22 ; C12N15/113
摘要：
Compositions for specifically cleaving target sequences in retroviruses include nucleic acids encoding a Clustered Regularly Interspace Short Palindromic Repeat (CRISPR) associated endonuclease and a guide RNA sequence complementary to a target sequence in a retrovirus and a receptor used by a retrovirus for infecting a cell. The CRISPR construct edits, for example, proviral HIV DNA, thereby eliminating the provirus from an infected cell and simultaneously edits a viral receptor, e.g. CCR5 preventing infection and reinfection of the host.
信息查询
